|
|
Article: Par Pharmaceutical Receives Final Approval to Market Generic Accupril(R) Tablets.
- Article from:
- PR Newswire
- Article date:
- December 22, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Under Licensing Agreement with Amide Pharmaceutical, Par Will Begin Shipping Quinapril Hydrochloride Tablets Immediately
Par Pharmaceutical Companies, Inc. today announced that its licensing partner, Amide Pharmaceutical, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for quinapril hydrochloride (HCl) tablets. The product was developed by Par's wholly-owned subsidiary, Kali Laboratories, Inc. Quinapril HCl, an angiotensin-converting enzyme (ACE) inhibitor, is the generic version of Pfizer's Accupril(R) and is used primarily for the treatment of hypertension. In 2003, U.S. sales of ...